Showing results (1-10 of 826) with videos related to
Sort By:
Pageof 83
Med (New York, N.Y.)|November 23, 2021
Reduced antibody activity against SARS-CoV-2 B.1.617.2 delta virus in serum of mRNA-vaccinated individuals receiving tumor necrosis factor-α inhibitorsRita E Chen, Matthew J Gorman, Daniel Y Zhu, et al.Med (New York, N.Y.)|February 8, 2022
A combination of two human neutralizing antibodies prevents SARS-CoV-2 infection in cynomolgus macaquesRonald R Cobb, Joseph Nkolola, Pavlo Gilchuk, et al.Med (New York, N.Y.)|October 25, 2021
Tuberculosis endotypes to guide stratified host-directed therapyAndrew R DiNardo, Tomoki Nishiguchi, Sandra L Grimm, et al.Med (New York, N.Y.)|October 7, 2021
Invariant Natural Killer T cells coordinate removal of senescent cellsShivani Arora, Peter J Thompson, Yao Wang, et al.Med (New York, N.Y.)|January 24, 2022
Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipientsNicholas Kim Huat Khoo, Joey Ming Er Lim, Upkar S Gill, et al.Med (New York, N.Y.)|March 9, 2022
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variantsSho Miyamoto, Takeshi Arashiro, Yu Adachi, et al.Med (New York, N.Y.)|February 28, 2022
Structural Discrimination in Emergency Care: How a Sick System Affects Us AllRenee Y Hsia, Stefany ZagorovMed (New York, N.Y.)|January 14, 2023
Ethics in pediatric researchMed (New York, N.Y.)|January 14, 2023
On blinding and suicide risk in a recent trial of psilocybin-assisted therapy for treatment-resistant depressionNatalie GukasyanMed (New York, N.Y.)|August 29, 2025
Anti-PD-1 antibody plus anlotinib vs. anlotinib alone in patients with refractory chondrosarcoma: A multicenter, non-randomized phase 2 FLAIL-C trialBinghao Li, Lu Xie, Junbo Liang, et al.Pageof 83